Triumvira Begins Phase I/II Trial for TAC101-CLDN18.2 Solid Tumor Therapy

In a recent development, Triumvira Immunologics, a company specializing in the creation of innovative T cell therapies for solid tumor treatment, has reached a significant milestone. The clinical-stage firm has commenced dosing for the first patient in its TACTIC-3 trial, a Phase I/II clinical study (NCT05862324). This study is focused on evaluating the safety and effectiveness of TAC101-CLDN18.2, an advanced cell therapy that utilizes genetically modified autologous T cells. These cells are engineered to express a T-cell Antigen Coupler (TAC), which targets Claudin 18.2, a protein that is overexpressed in various solid tumors, notably gastric cancer.

Dr. Andreas Bader, Chief Scientific Officer at Triumvira, highlighted Claudin 18.2 as an ideal target for cell therapy due to its limited presence in normal tissues and its heightened expression in certain cancer types. The company's Chief Medical Officer, Dr. Deyaa Adib, expressed enthusiasm about the potential of TAC101-CLDN18.2 to fill a significant therapeutic void for solid tumors, particularly for those that are Claudin 18.2 positive. The therapy is anticipated to be beneficial for patients with gastric, lung, ovarian, and pancreatic cancers, where there is currently a lack of approved treatments against Claudin 18.2.

The TACTIC-3 study is designed to assess the safety profile, determine the recommended Phase II dose, and analyze the pharmacokinetic behavior and efficacy of TAC101-CLDN18.2 in patients who have undergone a minimum of two prior treatments. For patients with pancreatic ductal adenocarcinoma, the study allows for inclusion based on one prior line of antineoplastic therapy. Eligibility also extends to subjects undergoing current therapies without demonstrated benefits, provided there was no measurable disease at the study's outset.

Triumvira Immunologics is recognized for its pioneering work in T cell therapies, utilizing its proprietary TAC technology to activate T cell functions in a manner distinct from other therapies like CAR-T and engineered TCR therapies. The company's goal is to develop clinically safe and effective treatments that can be re-administered as needed. In addition to Claudin 18.2, Triumvira is targeting other tumor-associated antigens such as HER2, GUCY2C, and GPC3. The company operates from locations in San Diego, Austin, Texas, and Hamilton, Ontario.
How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!